

In the Specification

Please substitute the following paragraphs on page 6, beginning at line 9 through to page 7,

line 2:

Figure 5: binding of OX40L fragments to OX40R-IgG₁. (A) sequence of human OX40L (SWISSPROT Acc. No. P23510; SEQ ID NO: 1), with the indication of the position of main protein domains (on the top of the sequence), together with the sequences corresponding to the peptides tested by the AlphascreenTM-based competition assay or the mouse OX40L-derived peptides P-OX-1 (SEQ ID NO: 14) and P-OX-2 (SEQ ID NO: 15) (on the bottom of the sequence; non-identical amino acids are indicated). (B) inhibition of binding of OX40R-IgG₁ to OX40L-CD8 by the peptides P4, P5, and a control without any peptide.

Figure 6: binding of P5-derived peptides (SEQ ID NOs: 6 and 8-12) to OX40R-IgG₁. (A) sequence of peptide P5 (SEQ ID NO: 6), aligned with mouse OX40L-derived peptide P-OX-1 (SEQ ID NO: 14) (Stuber E and Strober W, 1996; indicates non conservative substitution and . indicates conservative substitutions, as indicated in Table I) and with the sequence of the P5-derived peptides tested with the AlphascreenTM-based competition assay. The peptide P5-1a is the boxed sequence in P5-1. (B) Inhibition of binding of OX40R-IgG₁ to OX40L-CD8 by the peptide P5-1 in the AlphascreenTM-based competition assay, compared with the effect provided by other fragments of peptide P5.

Please substitute Figure 6 with new Figure 6 (page 6/7) attached hereto.

Please replace original pages 1-5 (Sequence Listing) with new pages 1-5 attached hereto.